RT Journal Article
T1 Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
A1 Pérez-Belmonte, Luis M.
A1 Ricci, Michele
A1 Sanz-Cánovas, Jaime
A1 Millán-Gómez, Mercedes
A1 Osuna-Sánchez, Julio
A1 Ruiz-Moreno, M Isabel
A1 Bernal-López, M Rosa
A1 López-Carmona, María D.
A1 Jiménez-Navarro, Manuel
A1 Gómez-Doblas, Juan J.
A1 Lara, José P.
A1 Gómez-Huelgas, Ricardo
K1 Type 2 diabetes
K1 Heart failure
K1 Empagliflozin
K1 Hospitalization
K1 Diabetes mellitus tipo 2
K1 Insuficiencia cardíaca
K1 Hospitalización
K1 Inhibidores del cotransportador de sodio-glucosa 2
AB There is little evidence on the use of sodium-glucose cotransporter 2 inhibitors in hospitalised patients. This work aims to analyse the glycaemic and clinical efficacy and safety of empagliflozin continuation in patients with type 2 diabetes hospitalised for acute decompensated heart failure. This real-world observational study includes patients treated using our in-hospital antihyperglycaemic regimens (basal-bolus insulin vs. empagliflozin-basal insulin) between 2017 and 2020. A propensity matching analysis was used to match a patient on one regimen with a patient on the other regimen. Our primary endpoints were the differences in glycaemic control, as measured via mean daily blood glucose levels, and differences in the visual analogue scale dyspnoea score, NT-proBNP levels, diuretic response, and cumulative urine output. Safety endpoints were also analysed. After a propensity matching analysis, 91 patients were included in each group. There were no differences in mean blood glucose levels (152.1 ± 17.8 vs. 155.2 ± 19.7 mg/dL, p = 0.289). At discharge, NT-proBNP levels were lower and cumulative urine output greater in the empagliflozin group versus the basal-bolus insulin group (1652 ± 501 vs. 2101 ± 522 pg/mL, p = 0.032 and 16,100 ± 1510 vs. 13,900 ± 1220 mL, p = 0.037, respectively). Patients who continued empagliflozin had a lower total number of hypoglycaemic episodes (36 vs. 64, p < 0.001). No differences were observed in adverse events, length of hospital stay, or in-hospital deaths. For patients with acute heart failure, an in-hospital antihyperglycaemic regimen that includes continuation of empagliflozin achieved effective glycaemic control, lower NT-proBNP, and greater urine output. It was also safer, as it reduced hypoglycaemic episodes without increasing other safety endpoints.
PB MDPI
YR 2021
FD 2021-08-12
LK http://hdl.handle.net/10668/3925
UL http://hdl.handle.net/10668/3925
LA en
NO Pérez-Belmonte LM, Ricci M, Sanz-Cánovas J, Millán-Gómez M, Osuna-Sánchez J, Ruiz-Moreno MI, et al. Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. J Clin Med. 2021 Aug 12;10(16):3540
DS RISalud
RD Apr 11, 2025